icad inc (ICAD) - Total Assets
Based on the latest financial reports, icad inc (ICAD) holds total assets worth $39.47 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of icad inc to assess how comfortably operating cash covers total debt obligations.
icad inc - Total Assets Trend (1987–2024)
This chart illustrates how icad inc's total assets have evolved over time, based on quarterly financial data. See icad inc (ICAD) net assets for net asset value and shareholders' equity analysis.
icad inc - Asset Composition Analysis
Current Asset Composition (December 2024)
icad inc's total assets of $39.47 Million consist of 70.4% current assets and 29.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.8% |
| Accounts Receivable | $7.21 Million | 19.2% |
| Inventory | $756.00K | 2.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $101.00K | 0.3% |
| Goodwill | $8.36 Million | 22.3% |
Asset Composition Trend (1987–2024)
This chart illustrates how icad inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see icad inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: icad inc's current assets represent 70.4% of total assets in 2024, an increase from 46.7% in 1987.
- Cash Position: Cash and equivalents constituted 45.8% of total assets in 2024, up from 1.1% in 1987.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, a decrease from 33.0% in 1987.
- Asset Diversification: The largest asset category is goodwill at 22.3% of total assets.
icad inc Competitors by Total Assets
Key competitors of icad inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
icad inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.66 | 4.71 | 2.79 |
| Quick Ratio | 3.57 | 4.59 | 2.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $20.43 Million | $22.88 Million | $22.90 Million |
icad inc - Advanced Valuation Insights
This section examines the relationship between icad inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.45 |
| Latest Market Cap to Assets Ratio | 2.83 |
| Asset Growth Rate (YoY) | -9.4% |
| Total Assets | $37.54 Million |
| Market Capitalization | $106.31 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values icad inc's assets at a significant premium (2.83x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: icad inc's assets decreased by 9.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for icad inc (1987–2024)
The table below shows the annual total assets of icad inc from 1987 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $37.54 Million | -9.36% |
| 2023-12-31 | $41.42 Million | -19.90% |
| 2022-12-31 | $51.70 Million | -16.86% |
| 2021-12-31 | $62.19 Million | +11.89% |
| 2020-12-31 | $55.58 Million | +33.14% |
| 2019-12-31 | $41.75 Million | +31.54% |
| 2018-12-31 | $31.74 Million | -1.23% |
| 2017-12-31 | $32.13 Million | -16.87% |
| 2016-12-31 | $38.65 Million | -20.54% |
| 2015-12-31 | $48.64 Million | -48.13% |
| 2014-12-31 | $93.77 Million | +59.16% |
| 2013-12-31 | $58.92 Million | -1.80% |
| 2012-12-31 | $59.99 Million | +15.90% |
| 2011-12-31 | $51.76 Million | -44.95% |
| 2010-12-31 | $94.03 Million | +28.09% |
| 2009-12-31 | $73.41 Million | +0.30% |
| 2008-12-31 | $73.19 Million | +18.56% |
| 2007-12-31 | $61.73 Million | +2.39% |
| 2006-12-31 | $60.29 Million | -2.01% |
| 2005-12-31 | $61.53 Million | -5.54% |
| 2004-12-31 | $65.14 Million | +3.95% |
| 2003-12-31 | $62.66 Million | +140.29% |
| 2002-12-31 | $26.08 Million | +526.69% |
| 2001-12-31 | $4.16 Million | -30.02% |
| 2000-12-31 | $5.95 Million | +4.31% |
| 1999-12-31 | $5.70 Million | -10.94% |
| 1998-12-31 | $6.40 Million | -9.86% |
| 1997-12-31 | $7.10 Million | -44.53% |
| 1996-12-31 | $12.80 Million | -30.81% |
| 1995-12-31 | $18.50 Million | -14.35% |
| 1994-12-31 | $21.60 Million | +19.34% |
| 1993-12-31 | $18.10 Million | -7.65% |
| 1992-12-31 | $19.60 Million | +29.80% |
| 1991-12-31 | $15.10 Million | -31.05% |
| 1990-12-31 | $21.90 Million | -5.19% |
| 1989-12-31 | $23.10 Million | +22.22% |
| 1988-12-31 | $18.90 Million | +110.00% |
| 1987-12-31 | $9.00 Million | -- |
About icad inc
iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurat… Read more